PRESS RELEASE
Friday, 2nd February 2018, Mumbai

GlaxoSmithKline Pharmaceuticals Limited delivers strong Q3 performance with Revenue of 704 Cr.

GlaxoSmithKline Pharmaceuticals Limited today declared its financial results for the quarter ended 31st December 2017. Revenue from Operations for the quarter ended 31st December 2017 at Rs.704 crores was flat as compared to the same prior year period. The Revenue is deflated by an estimated 5% during the quarter, that is predominately profit neutral, and arising from the impact of the newly implemented GST rates. Consequently, the Revenue of this quarter is not directly comparable to prior year quarters due to the dynamics and rates from GST.

Profit Before Tax (PBT) at Rs. 140 crores and Profit After Tax (PAT) at Rs 90 crores grew by 79% and 69% respectively against the same prior year period. This needs to be viewed in light of a low prior year base due to impacts from demonetisation.

Commenting on the results, A. Vaidheesh, Managing Director, GlaxoSmithKline Pharmaceuticals Limited said,

“Overall underlying performance, excluding the impacts of GST and prior year disposals, is supported by high single to double digit volume growth on our key brands and therapy areas. An improved product mix, other credits to consumption, lower stock impairments combined with optimisation of costs contributed to an EBITDA margin of 21% in the quarter.

During the quarter the Company has received the money in advance towards disposal of Thane Land. The transfer of the said land will happen upon obtaining all relevant statutory and other permissions. The amount received has been accounted as advance against sale of land.”

About GlaxoSmithKline Pharmaceuticals Limited

GSK - a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk-india.com

Media Contacts:
Ransom D’Souza
Vice President Corporate Communications and Government Affairs
Email: ransom.a.dsoouza@gsk.com
Tel: +91 22 24959203